Top Page
Challenger Limited
(Sydney:CGF)
Challenger Limited (CGF) vs. S&P 500 (SPY)
Challenger Limited Business Overview & Revenue Model
Challenger Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.58B | 3.28B | 2.23B | -414.30M | 3.03B | 1.51B | Gross Profit |
| 2.90B | 635.90M | 652.20M | 1.36B | 1.79B | 1.38B | EBIT |
| 2.95B | 2.65B | 1.02B | -339.80M | 1.09B | -242.40M | EBITDA |
| 488.80M | 938.50M | 780.70M | 348.20M | 1.14B | -390.80M | Net Income Common Stockholders |
| 146.00M | 129.90M | 287.50M | 253.70M | 592.30M | -416.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 978.40M | 573.20M | 593.40M | 733.10M | 989.40M | 661.90M | Total Assets |
| 17.55B | 33.41B | 30.98B | 29.74B | 29.99B | 28.57B | Total Debt |
| 0.00 | 7.13B | 5.89B | 5.85B | 6.39B | 7.81B | Net Debt |
| -978.40M | 6.55B | 5.30B | 5.11B | 5.40B | 7.14B | Total Liabilities |
| 5.99B | 29.53B | 26.81B | 25.75B | 26.17B | 25.33B | Stockholders Equity |
| 1.85B | 3.88B | 4.16B | 3.99B | 3.83B | 3.25B |
| Cash Flow | Free Cash Flow | ||||
| 341.00M | 841.80M | 1.27B | 2.48B | 2.56B | 475.60M | Operating Cash Flow |
| 342.00M | 843.70M | 1.27B | 2.49B | 2.58B | 484.90M | Investing Cash Flow |
| -643.40M | -1.94B | -1.34B | -2.12B | -865.00M | -1.48B | Financing Cash Flow |
| 270.10M | 1.08B | -35.00M | -619.80M | -1.38B | 863.30M |
Challenger Limited Technical Analysis
Challenger Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €1.32B | 6.02 | 23.27% | 9.10% | -9.29% | 12.94% | |
70 Outperform | $4.88B | 33.36 | 3.85% | 6.05% | 17.95% | -34.24% | |
70 Outperform | $21.26B | 15.07 | 9.52% | 5.59% | -11.75% | ― | |
63 Neutral | $12.32B | 9.52 | 7.97% | 79.23% | 12.77% | -4.57% | |
55 Neutral | €1.96B | ― | -24.47% | 8.28% | 5.36% | -846.00% | |
50 Neutral | $2.49B | ― | -7.21% | 2.51% | -8.26% | -259.91% | |
44 Neutral | AU$3.06B | 17.07 | 4.84% | 1.80% | 19.36% | 1261.54% |
Challenger Limited Corporate Events
Challenger Limited has announced a revision to its 2025 financial calendar, specifically changing the date for the 2025 Investor Day and scheduling the 2026 first quarter update for October 16, 2025. This adjustment in the financial calendar is crucial for stakeholders to align their expectations and plans with the company’s updated timeline, ensuring transparency and efficient communication with investors.
Challenger Limited has announced a change in its substantial holding in Imricor Medical Systems, Inc., increasing its voting power from 6.26% to 7.27%. This adjustment in holdings reflects Challenger’s strategic investment decisions, potentially impacting its influence within Imricor and indicating a strengthened position in the market.
Challenger Limited has announced a change in its substantial holding in IRESS Limited, indicating an adjustment in its voting power from 8.23% to 7.20%. This change reflects Challenger’s ongoing management of its investment portfolio and may impact its influence within IRESS Limited, potentially affecting stakeholders’ interests and market perceptions.
Challenger Limited has announced a change in the director’s interest notice, indicating that Director Lisa Gray has increased her indirect interest in the company by acquiring 8,333 ordinary shares through an on-market trade. This acquisition raises her total holdings to 16,436 shares, reflecting a continued confidence in the company’s prospects. Such changes in director holdings can signal potential strategic shifts or confidence in the company’s future performance, which may be of interest to investors and stakeholders.
Challenger Limited has announced a change in its substantial holding in Amplitude Energy Limited, increasing its voting power from 7.66% to 9.09%. This change reflects a strategic move by Challenger to strengthen its influence and investment in Amplitude Energy, potentially impacting the company’s market positioning and stakeholder interests.
TAL Dai-ichi Life, a subsidiary of Dai-ichi Life Holdings, has acquired a 15.1% minority stake in Challenger Limited from MS&AD Insurance Group Holdings at a premium price. This strategic investment is expected to strengthen Challenger’s growth strategy and provide financial confidence to more Australians in retirement. The existing reinsurance partnership with MS Primary will remain unaffected, ensuring continued collaboration and value creation. The acquisition is subject to regulatory approvals, and MS&AD’s representative will step down from Challenger’s board following the sale.
Challenger Limited, a company listed on the Australian Securities Exchange (ASX) under the symbol CGF, is involved in a significant transaction as TAL Dai-ichi Life Australia Pty Ltd (TAL) has entered into a conditional agreement to acquire shares held by Citicorp Nominees Pty Limited on behalf of MS&AD Insurance Group Holdings, Inc. This acquisition marks a substantial change in shareholding, as indicated by the Notice of Initial Substantial Holder filed under the Corporations Act 2001. The transaction could have implications for Challenger Limited’s market position and stakeholder dynamics.
Challenger Limited has announced a change in substantial holdings, as State Street Corporation and its subsidiaries have ceased to be substantial holders as of March 31, 2025. This change in holdings may impact the company’s voting securities and could influence its market dynamics and stakeholder relationships.
Challenger Limited has issued a notice regarding its voting shares and derivative exposures. The company currently holds 2,009,509 ordinary shares, representing 0.2906% of the total shares in Challenger. The notice details changes in share interests and derivative exposures since the previous notice, including acquisitions and forfeitures of shares by the Challenger Performance Plan Trust. This update is part of the company’s compliance with the Corporations Act 2001.
Challenger Limited announced the resignation of Mr. Hiroyuki Iioka as an Alternate Director to Mr. Masahiko Kobayashi, effective March 31, 2025, following his retirement from MS&AD Insurance Group Holdings Inc. This change in the board of directors may have implications for the company’s governance and strategic direction, potentially affecting stakeholders’ interests.
Challenger Limited has announced the acquisition of a substantial holding by State Street Corporation and its subsidiaries, including State Street Global Advisors and State Street Bank and Trust Company. This move signifies a significant shift in the company’s shareholder structure, potentially impacting its strategic direction and market positioning. The acquisition involves a substantial number of voting shares, indicating State Street’s increased influence in Challenger Limited’s corporate governance.
Challenger Limited has announced a significant change in its shareholder structure, with the State Street Corporation and its subsidiaries becoming substantial holders. This development indicates a strategic shift in the company’s ownership, potentially impacting its governance and decision-making processes. The involvement of major financial entities like State Street Global Advisors and The Goldman Sachs Group suggests an increased focus on institutional investment, which could influence Challenger Limited’s market strategy and stakeholder relations.
Challenger Limited announced the issue price for its interim 2025 Dividend Reinvestment Plan (DRP) at $5.5314 per share, based on the average share prices over ten trading days. The DRP participation rate was 2% of issued capital, and the plan was neutralized by purchasing 352,203 ordinary shares worth approximately $2 million on the market, which were issued to DRP participants.
Challenger Limited has announced a change in its substantial holding in IRESS Limited, a financial technology company. This adjustment in voting power, from 10.37% to 9.25%, indicates a strategic shift in Challenger’s investment portfolio, potentially impacting its influence in IRESS and reflecting its broader market strategy.
Challenger Limited has released a presentation for the Jefferies Asia Forum, highlighting its focus on financial security for retirement. This announcement underscores Challenger’s commitment to maintaining its leadership in the annuities market and could impact its market positioning and stakeholder engagement.
Challenger Limited has announced an update regarding its dividend distribution for its ordinary fully paid securities, with a focus on the Dividend Reinvestment Plan (DRP) price. The update pertains to the dividend distribution for the six-month period ending December 31, 2024, and follows a previous announcement made on February 28, 2025. This update is significant for shareholders as it provides clarity on the DRP price, which can impact investment decisions and the company’s financial planning.
Challenger Limited has announced its initial substantial holding in Smartgroup Corporation Ltd, acquiring a 5.04% voting power. This strategic move signifies Challenger’s interest in expanding its influence and investment portfolio within the financial services sector, potentially impacting its market positioning and stakeholder interests.
Challenger Limited has announced its status as an initial substantial holder in Integral Diagnostics Limited, acquiring a significant voting power of 5.40%. This strategic move enhances Challenger’s investment portfolio and may influence its market positioning, potentially impacting stakeholders by increasing its influence in the healthcare diagnostics sector.
Challenger Limited has announced a new distribution for its Capital Notes 3, with a payment amount of AUD 1.51 per note. The distribution is scheduled for payment on May 26, 2025, with a record date of May 16, 2025, and an ex-date of May 15, 2025. This announcement reflects Challenger’s ongoing commitment to providing returns to its investors, although the distribution remains discretionary and subject to certain conditions. The announcement may influence investor sentiment and the company’s market positioning in the financial services sector.
Challenger Limited has announced a new dividend distribution for its security, CGFPD, with a distribution amount of AUD 1.33. The payment is scheduled for May 26, 2025, following the record date on May 16, 2025. This announcement reflects Challenger’s ongoing commitment to providing returns to its stakeholders, although the distributions are discretionary and contingent upon certain conditions being met.
Challenger Limited has announced its plan to neutralize the impact of shares allocated under its Dividend Reinvestment Plan (DRP) for the 2025 interim dividend. The company has appointed UBS Securities Australia Limited to execute an on-market share purchase of up to $2 million to meet its DRP obligations. This move is part of Challenger’s strategy to manage its share capital effectively, ensuring that DRP participants receive their shares without needing to take any action.
Challenger Limited has expressed strong support for APRA’s proposed changes to capital settings for annuity products, which are expected to significantly benefit Australian retirees, the industry, and the economy. The changes aim to lower required capital levels for annuities, reduce risks to life insurers’ balance sheets, and promote innovation and competition in the lifetime income market. Challenger sees this as a pivotal regulatory update that will enhance financial confidence in retirement and stimulate investment in long-term assets.
Challenger Limited has announced a change in its substantial holding in Qube Holdings Limited. The company’s voting power in Qube Holdings has decreased from 8.24% to 7.18%, reflecting a shift in its investment strategy. This change could impact Challenger’s influence within Qube Holdings and may have implications for its stakeholders as it adjusts its investment portfolio.
Challenger Limited announced a strong financial performance for the first half of 2025, with a 12% increase in normalised net profit after tax to $225 million and a 28% rise in statutory NPAT to $72 million. The company’s Life business reported significant growth in annuity sales, particularly in retail lifetime and Japanese markets, while its Funds Management segment expanded its investment strategies. Challenger also made strategic advancements in technology and partnerships, including transitioning investment administration to State Street and modernizing its Life business infrastructure, which are expected to support future growth and enhance operational efficiencies.
Challenger Limited reported strong financial results for the first half of the 2025 fiscal year, with a 12% increase in normalised net profit after tax to $225 million and a 28% rise in statutory net profit to $72 million. The company’s Life business showed robust growth in annuity sales, particularly in longer-term and Japanese markets, while its Funds Management segment expanded its investment strategies and affiliate network. Challenger’s strategic initiatives, including technology modernization and partnerships with firms like State Street, have positioned it for continued growth and operational efficiency. The company remains well-capitalized, supporting future expansion and stakeholder confidence, as reflected by a 12% increase in its interim dividend.
Challenger Limited’s 1H25 financial highlights reveal strategic progress with key performance indicators showing a positive outlook for FY25. The company’s interim financial report, reviewed by Ernst & Young, highlights its continued focus on growth and market positioning in the retirement income sector, despite inherent uncertainties and risks.
Challenger Limited has issued a statement acknowledging the Traditional Owners of Country throughout Australia. The company pays respect to Elders past and present and recognizes the continuing connection Aboriginal and Torres Strait Islander peoples have to the land, highlighting their unique and rich contribution to society.
Challenger Limited has reported a strong performance for the first half of FY25, achieving a 12% increase in normalised net profit after tax (NPAT) to $225 million. The company’s strategic focus on longer duration annuity sales has resulted in record sales in both retail lifetime and Japanese annuities. Additionally, group assets under management increased by 3% to $131 billion, and the company declared a fully franked interim dividend of 14.5 cents per share, reflecting a 12% rise. These results highlight Challenger’s effective execution of its growth strategy and the successful re-platforming of its customer and investment technology, setting a strong foundation for future growth and continued market leadership.
Challenger Limited has released its 2025 Interim Financial Report, outlining key dates for dividend payments, performance updates, and its Annual General Meeting. The report details the company’s strategic progress, performance indicators, and financial statements, reflecting Challenger’s continued focus on growth and shareholder value.
Challenger Limited reported a 4.4% increase in revenue to $1,569.3 million and a 28.2% rise in net profit attributable to equity holders to $72.2 million for the six months ending December 2024. The company’s normalised net profit after tax, a preferred measure, grew by 12.2% to $225.2 million. An interim dividend of 14.5 cents per share was declared, fully franked, marking an 11.5% increase from the previous period. The Board will continue the Dividend Reinvestment Plan, issuing new shares without discount. These results indicate strong financial performance, potentially enhancing Challenger’s market positioning and providing positive implications for stakeholders.
Challenger Limited has announced that it is no longer a substantial holder in Sigma Healthcare Ltd, following a reduction in its shareholding due to Sigma’s issuance of new securities. This change, effective from February 12, 2025, may impact Challenger’s influence in Sigma Healthcare, possibly altering its strategic investment approach and affecting stakeholders involved with both companies.